Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Moderate Buy consensus from 11 analysts (1 sell, 1 hold, 8 buy, 1 strong buy) with an average 12‑month price target of $20.45.
• Shares trade around $9.01 with a market cap of $1.16B, a negative PE (-2.92) and a 52‑week range of $2.25–$10.21; the company recently reported quarterly EPS of ($1.00), missing estimates by $0.59.
• Compass is a clinical‑stage biotech developing psilocybin therapy (COMP360) for treatment‑resistant depression, with a Phase IIb program that has received Breakthrough Therapy designation.

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $20.4545.

CMPS has been the topic of several research analyst reports. B. Riley Financial initiated coverage on Compass Pathways in a report on Friday, April 24th. They set a "buy" rating and a $17.00 target price on the stock. Royal Bank Of Canada increased their target price on Compass Pathways from $21.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, February 18th. Canaccord Genuity Group decreased their target price on Compass Pathways from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, March 26th. Compass Point set a $15.00 price target on Compass Pathways in a research note on Thursday, February 12th. Finally, Morgan Stanley decreased their price target on Compass Pathways from $18.00 to $16.00 and set an "overweight" rating on the stock in a report on Wednesday, March 25th.

Compass Pathways Price Performance

Shares of CMPS stock opened at $9.01 on Monday. The stock's fifty day moving average is $6.77 and its 200-day moving average is $6.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.77 and a current ratio of 0.77. The stock has a market capitalization of $1.16 billion, a PE ratio of -2.92 and a beta of 2.39. Compass Pathways has a 52 week low of $2.25 and a 52 week high of $10.21.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last announced its earnings results on Tuesday, March 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.59). Equities research analysts expect that Compass Pathways will post -1.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Pathways

Hedge funds have recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd bought a new position in Compass Pathways in the fourth quarter valued at about $38,000. Caitong International Asset Management Co. Ltd bought a new position in Compass Pathways in the fourth quarter valued at about $47,000. Advisory Services Network LLC bought a new position in Compass Pathways in the third quarter valued at about $41,000. North Star Investment Management Corp. boosted its holdings in Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company's stock valued at $42,000 after acquiring an additional 7,000 shares during the last quarter. Finally, BIT Capital GmbH bought a new position in Compass Pathways in the third quarter valued at about $54,000. Institutional investors own 46.19% of the company's stock.

Compass Pathways Company Profile

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.